DOI: 10.1158/1541-7786.mcr-26-0046 ISSN: 1541-7786

Calreticulin exposure is a critical mediator of high-dose vitamin C-induced immune surveillance in the tumor microenvironment

Alessandro Cavaliere, Federica Maione, Marco Macagno, Vito Amodio, Rosaria Chila, Marcello Turi, Marc Escobosa Olmo, Giovanni Germano, Simona Lamba, Daniele Oddo, Marta Pandini, Chiara Baretta, Anita Brignacca, Valeria Pessei, Noemi Congiusta, Elena Perez, Daniela Grases, Alice Bartolini, Fabio Penna, Eduard Porta, Manel Esteller, Dieter Saur, Roland Rad, Annamaria Gulla, Alberto Bardelli, Federica Di Nicolantonio

Abstract

High-dose vitamin C (vitC) has shown superior anticancer activity in immunocompetent compared with immunodeficient mice, suggesting an immunodependent mechanism of action. Because high-dose vitC generates substantial reactive oxygen species (ROS), we hypothesized that ROS could induce immunogenic cell death (ICD), a regulated form of cell death characterized by the release of damage-associated molecular patterns (DAMPs) that enhance antigen presentation and promote antitumor immunity. Spatial transcriptomic and immunofluorescence analyses were performed on breast and colon tumors from mice treated with high-dose vitC to quantify oxidative stress, DAMP mobilization, and immune cell infiltration. To dissect the functional role of ROS and ICD, mice were treated with high-dose vitC in combination with the antioxidant N-acetylcysteine or an antibody blocking calreticulin (an early DAMP essential for ICD induction). VitC treatment caused marked oxidative stress in tumors from both immunocompetent and immunocompromised mice; however, tumor growth inhibition occurred exclusively in immunocompetent animals. High-dose vitC triggered ROS-dependent exposure and release of the DAMPs calreticulin and HMGB1, respectively. This was accompanied by substantial remodeling of the tumor microenvironment, including increased infiltration of cytotoxic CD8⁺ T cells and natural killer cells, and a reduction in immunosuppressive regulatory T cells. Blocking calreticulin effectively disrupted the ICD cascade, prevented immune microenvironment remodeling, and completely abrogated the antitumor efficacy of vitC. Collectively, our study indicates that high-dose vitC promotes ICD by mobilizing calreticulin and HMGB1, and that calreticulin is a determinant of its immune-mediated antitumor activity. Implications: vitC induces ICD, supporting its use as an adjuvant to anticancer immunotherapy.

More from our Archive